Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Advantech Europe

Events

18 Feb 2016 - 20 Feb 2016
19 Feb 2016 - 21 Feb 2016
27 Feb 2016 - 03 Mar 2016

NMR-Based Diabetes Risk Index Helps to Identify Normal-Weight Individuals at High Risk of Progressing to Type 2 Diabetes

By Medimaging International staff writers
Posted on 09 Jul 2014
Print article
A nuclear magnetic resonance (NMR)-based diabetes risk index (DRI) is being used to identify normal-weight individuals at high risk of progressing to type 2 diabetes, and may enable a more comprehensive risk assessment and intervention in at-risk patients.

LipoScience, Inc. (Raleigh NC, USA), a diagnostic company that develops personalized NMR diagnostics to further the quality of patient care in cardiovascular, metabolic, and other diseases, presented data demonstrating the utility of the company’s technology on June 14, 2014, at the 74th Scientific Sessions of the American Diabetes Association (ADA), held in San Francisco (CA, USA), and suggests that the DRI may enable more timely and focused risk assessment and intervention in at-risk individuals regardless of body weight, potentially preventing or slowing their progression to type 2 diabetes.

“Many clinicians are challenged about how to effectively manage patients with ‘intermediate’ blood glucose levels ranging from 90 to 110 mg/dL, as within this range there is often ambiguity as to whether a patient will progress to type 2 diabetes,” commented Margery Connelly, PhD, vice president, translational research of LipoScience. “The ambiguity is particularly pronounced in normal-weight individuals, who do not typically present with overtly visible risk factors. With our simple-to-use diabetes risk index, clinicians now have a tool to help them identify high-risk patients, providing guidance for implementing targeted risk-reduction strategies.”

The DRI is a clinical lab test that uses LipoScience’s proprietary NMR-derived markers of insulin resistance, inflammation, and potentially impaired B-cell function to determine a patient's risk of progressing to type 2 diabetes. DRI provides researchers and healthcare providers with the means to assess a patient’s risk of progressing to diabetes at any given level of fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), or body mass index (BMI).

The investigators used NMR data gathered at baseline from participants in the Multi-Ethnic Study of Atherosclerosis (MESA), to develop the DRI assay, and then used data from and the Insulin Resistance Atherosclerosis Study (IRAS) to verify its ability to stratify a patient’s risk of progressing to type 2 diabetes. To determine whether the DRI score was capable of identifying normal-weight individuals with a high likelihood of developing diabetes, the investigators compared the percentage of patients progressing to type 2 diabetes across quartiles of the DRI score in three BMI categories—normal weight (BMI < 25), overweight (BMI 25–30), and obese (BMI ≥ 30). Regardless of the BMI category, as the DRI score increased there was an increased likelihood of becoming diabetic, even for patients whose BMI was within the normal range. Furthermore, DRI added predictive value independently of BMI in both the MESA and IRAS populations.

"Even in the absence of being overweight, DRI can help healthcare providers make a more timely prediction of whether a patient is on the path toward developing diabetes, before blood glucose reaches so-called ‘pre-diabetes’ levels,” noted William C. Cromwell, MD, chief medical officer of LipoScience. “By providing more precise risk-assessment information, DRI can facilitate initiation of individualized patient management strategies, while motivating high-risk patients to take steps to lower their risk.”

LipoScience is focused on the new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The NMR LipoProfile test, the company’s first proprietary test, is the only US Food and Drug Administration (FDA)-cleared blood test that directly quantifies low-density lipoprotein (LDL) particles and provides physicians and their patients with actionable information to personalize management of heart disease.

The Vantera clinical analyzer is the first FDA-cleared platform that utilizes NMR technology. Its ease of use and quick turnaround time helps maximize efficiency and throughput in the clinical laboratory.

Related Links:

LipoScience



Print article
OKI DATA

Channels

Radiography

view channel

No Proof That X-ray Radiation Causes Cancer

The widespread belief that radiation from X-rays can cause cancer is based on an invalid paradigm for estimating low-dose radiation exposure risk, according to a new study. According to researchers at Loyola University Medical Center (Maywood, IL, USA), the linear no-threshold (LNT) model, which is constantly used today... Read more

MRI

view channel

fMRI Could Help Identify New Painkillers

Measuring the brain's neural response to pain using functional magnetic resonance imaging (fMRI) may be a viable tool for evaluating the effectiveness of new pain medications, according to a new study. Researchers at John Radcliffe Hospital (Oxford, United Kingdom) and Oxford University (United Kingdom) conducted a double-blind,... Read more

Ultrasound

view channel
Image: The Verathon BladderScan Prime (Photo courtesy of Verathon).

Portable Ultrasound Device Quantifies Bladder Volume

A new portable three-dimensional (3D) ultrasound instrument helps reduce catheter-associated urinary tract infections (CAUTI) by reducing the use of catheters. The Verathon BladderScan Prime is a noninvasive... Read more

General/Advanced Imaging

view channel

Healthcare IT Manufacturer and Teleradiology Interoperability Expert Introduce New FHIR System

A new interoperability system that was launched at the 2015 Radiological Society of North America (RSNA) annual meeting in Chicago, USA, in November, 2015, is now being introduced into the market. The system enables seamless integration of third party enterprise imaging systems using the latest Fast Healthcare Interoperability... Read more

Imaging IT

view channel
Image: Photo of the virtual reality device mobile diagnostic imaging (Photo courtesy of RSNA).

Prototype of Virtual Reality Device with Potential for Diagnostic Imaging Presented

A prototype of a high-resolution mobile Virtual Reality (VR) diagnostic imaging device for radiologists was presented at the annual Radiological Society of North America (RSNA 2015) meeting in Chicago (IL, USA).... Read more

Industry News

view channel

Radiology Oncology Surgical Robot Devices Sector Could Reach USD 7.3 Billion by 2022

A new report has been published indicating that worldwide market for radiology oncology surgical robots market is growing mainly due to an aging world population, and the benefits the new technology can offer. Radiology oncology surgical robot technology provides opportunities to change cancer treatment methods, including... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.